Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness

V Kari, WY Mansour, SK Raul, SJ Baumgart, A Mund… - EMBO …, 2016 - embopress.org
V Kari, WY Mansour, SK Raul, SJ Baumgart, A Mund, M Grade, H Sirma, R Simon, H Will…
EMBO reports, 2016embopress.org
The CHD1 gene, encoding the chromo‐domain helicase DNA‐binding protein‐1, is one of
the most frequently deleted genes in prostate cancer. Here, we examined the role of CHD1
in DNA double‐strand break (DSB) repair in prostate cancer cells. We show that CHD1 is
required for the recruitment of CtIP to chromatin and subsequent end resection during DNA
DSB repair. Our data support a role for CHD1 in opening the chromatin around the DSB to
facilitate the recruitment of homologous recombination (HR) proteins. Consequently …
Abstract
The CHD1 gene, encoding the chromo‐domain helicase DNA‐binding protein‐1, is one of the most frequently deleted genes in prostate cancer. Here, we examined the role of CHD1 in DNA double‐strand break (DSB) repair in prostate cancer cells. We show that CHD1 is required for the recruitment of CtIP to chromatin and subsequent end resection during DNA DSB repair. Our data support a role for CHD1 in opening the chromatin around the DSB to facilitate the recruitment of homologous recombination (HR) proteins. Consequently, depletion of CHD1 specifically affects HR‐mediated DNA repair but not non‐homologous end joining. Together, we provide evidence for a previously unknown role of CHD1 in DNA DSB repair via HR and show that CHD1 depletion sensitizes cells to PARP inhibitors, which has potential therapeutic relevance. Our findings suggest that CHD1 deletion, like BRCA1/2 mutation in ovarian cancer, may serve as a marker for prostate cancer patient stratification and the utilization of targeted therapies such as PARP inhibitors, which specifically target tumors with HR defects.
embopress.org